US Stock Market Move | Will launch exclusive oral testosterone therapy Hims & Hers Health (HIMS.US) surges over 7%

On Wednesday, the stock price of Hims & Hers Health (HIMS.US) rose, with the stock up over 7% to $51.39 as of the time of writing. In terms of news, the company announced a partnership with testosterone therapy innovation leader Marius Pharmaceuticals to exclusively launch an oral testosterone medication KYZATREX on its platform by 2026. This medication has been approved by the US Food and Drug Administration and does not require injections, making it more convenient to use. According to clinical data, KYZATREX can help up to 96% of men restore normal testosterone levels and double their "free testosterone" levels. Free testosterone is closely related to energy, drive, and physical performance, and this medication maintains a lower rate of adverse reactions while improving efficacy.